Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 22, 2007

View Archived Issues

Novartis discovers a potent NPM-ALK kinase inhibitor

Hivenyl significantly reduces atopic dermatitis itch severity without sedation

VASTox joins European consortium to research new treatments for cancer

Pivotal study evaluates Aastrom's TRCs for osteonecrosis of the femoral head

Cervarix compared to Gardasil in new phase III study

Archemix and Merck KGaA sign aptamer agreement in cancer

FDA grants orphan drug status to VQD-001 for cutaneous leishmaniasis

Two phase I trials cleared to begin for Lymphoseek in prostate and colon cancers

Positive preclinical results with Endocyte's folate receptor-targeted immunotherapy

Lipsovir cold sore program makes progress

1207 shows no clear anesthetic effect in phase I study

Butyrylcholinesterase studied as chemical defense product in new phase I trial

Adherex acquires GSK's options to eniluracil

Enrollment completed in study of AZ-004 in agitated schizophrenic patients

Data on nitroflurbiprofen sets stage for clinical trials in DMD

Neuroprotection by humanin and one of its derivatives: an update

INNO-406 found effective in animal models of CNS Ph+ leukemia

Alimta launched in Japan for malignant pleural mesothelioma

Cipralex approved in Europe for OC

Full European approval for Sutent in advanced renal cell carcinoma

New therapeutic agents for ocular disorders disclosed in recent patent literature

Recent patents report novel analgesic agents

New agents for treating gastrointestinal disorders disclosed in recent patents

Inovelon approved in E.U. for Lennox-Gastaut syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...